Last reviewed · How we verify
NCT02287558
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
Phase 1 trial testing Pomalidomide in Hereditary Hemorrhagic Telangiectasia in 9 participants. Completed in 1 June 2019.
1 June 2019
Quick facts
| Lead sponsor | The Cleveland Clinic |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 27 January 2015 |
| Primary completion | 1 June 2019 |
| Estimated completion | 1 June 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Pomalidomide — full drug profile →
Conditions studied
- Hereditary Hemorrhagic Telangiectasia — all drugs for Hereditary Hemorrhagic Telangiectasia →
- Idiopathic Vascular Ectasia — all drugs for Idiopathic Vascular Ectasia →
Sponsor
The Cleveland Clinic
Who can join
18 and older, any sex, with Hereditary Hemorrhagic Telangiectasia or Idiopathic Vascular Ectasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate patients \> 18 years of age with transfusion-dependent gastrointestinal bleeding due to documented gastrointestinal vascular ectasia with or without concurrent hereditary hemorrhagic telangiectasia (HHT). This study will focus on documented bleeding sites in the small bowel, including the duodenum, jejunum and ileum. Eligible patients will have endoscopically-documented sites of vascular ectasia and will have required at least 4 units of blood transfusion or episodes of intravenous iron administration over the preceding four months.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding.
Albiñana V, Cuesta AM, Rojas-P I, Gallardo-Vara E, et al · · 2020 · cited 20× · PMID 32517280 · DOI 10.3390/jcm9061766 -
Advances in the Medical Management of Vascular Anomalies.
Ricci KW. · · 2017 · cited 18× · PMID 28955113 · DOI 10.1055/s-0037-1604297 -
Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia.
Ficany A, Del Alamo M, Bernabeu C, Shovlin CL, et al · · 2025 · PMID 41227119 · DOI 10.3390/jcm14217724 -
The Role of Medical Management in Vascular Anomalies.
White MH, Hawkins CM. · · 2024 · PMID 39524237 · DOI 10.1055/s-0044-1791538
Verify or expand the search:
- PubMed search for NCT02287558
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pomalidomide
Trials testing the same drug.
- NCT07463807 — Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carf · Phase 1, PHASE2 · not yet recruiting
- NCT06948084 — Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Darat · Phase 2 · not yet recruiting
- NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting
- NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting
- NCT07096778 — Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
Other recruiting trials for Hereditary Hemorrhagic Telangiectasia
Currently open trials in the same condition.
- NCT06659640 — A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) · Phase 1, PHASE2 · recruiting
- NCT04874558 — Ultra-low-dose Chest CT for HHT · active not recruiting
- NCT04404881 — Bevacizumab In Hereditary Hemorrhagic Telangiectasia · Phase 2 · active not recruiting
- NCT04469517 — Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia · recruiting
- NCT04150822 — CHORUS - Comprehensive HHT Outcomes Registry of the United States (Formerly OUR HHT Registry) · active not recruiting
Other The Cleveland Clinic trials
Trials by the same sponsor.
- NCT07218198 — Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension · NA · not yet recruiting
- NCT07442747 — Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS · NA · not yet recruiting
- NCT07471464 — Centered Surgery - Preoperative Counseling and Patient Satisfaction · recruiting
- NCT07073963 — Virtual Patient Groups for Sarcoidosis Associated Fatigue · NA · recruiting
- NCT07363343 — Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02287558 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Cleveland Clinic
- Last refreshed: 15 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02287558.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing